Intercell receives "The Vaccine Industry Excellence Award"

» Intercell's therapeutic Hepatitis C vaccine successfully concluded
Phase II clinical trials in February 2008 =

--------------------------------------------------------------------------------
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for
the content of this announcement.
--------------------------------------------------------------------------------

Wien (euro adhoc) - Vienna (Austria), April 24, 2008 - In the course of the
World Vaccine Congress in Washington D.C., USA, Intercell was awarded "The
Vaccine Industry Excellence Award" in the category "Best New Therapeutic
Vaccine" for its therapeutic Hepatitis C (HCV) vaccine candidate.

Earlier this year, Intercell's therapeutic vaccine candidate against HCV
successfully concluded Phase II clinical trials. The novel vaccine is designed
to stimulate T-cell responses against viral protein structures conserved
throughout the major HCV genotypes in order to reduce viral load in the blood of
chronically infected patients.

"We are pleased to receive this award for our novel therapeutic Hepatitis C
vaccine. The latest Phase II data provides a strong base to further strengthen
our Hepatitis C franchise and to accelerate our efforts towards a most valuable
potential component in a combination treatment for HCV," stated Alexander von
Gabain, Chief Scientific Officer of Intercell.

To improve and accelerate the development of a therapeutic Hepatitis C vaccine,
Intercell and its partner Novartis will take advantage of an enlarged antigen
portfolio and of IC31®, Intercell´s second-generation adjuvant.

With representatives from over 200 individual companies, the "World Vaccine
Congress", taking place in Washington D.C. (USA) from April 21-24, 2008, is one
of the largest and most important vaccine industry meetings this year.

Further inquiry note:
Intercell AG
Lucia Malfent
Head of Communications
Tel. +43 1 20620-303
[email protected]

end of announcement euro adhoc
--------------------------------------------------------------------------------

emitter: Intercell AG
Campus Vienna Biocenter 6
A-1030 Wien
phone: +43 1 20620-0
FAX: +43 1 20620-800
mail: [email protected]
WWW: www.intercell.com
sector: Biotechnology
ISIN: AT0000612601
indexes: ATX Prime, ATX
stockmarkets: official market: Wiener Börse AG
language: English

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | CNE

print